Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share: €-1.86 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8EM Editas Medicine Inc STU:8EM
51 GF Score
Price €2.51
GF Value €1.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Cyclically Adjusted FCF per Share?

Editas Medicine STU:8EM -3.46% 51 Cyclically Adjusted FCF per Share is €-1.86 as of Mar. 2026. GuruFocus rates STU:8EM with a GF Score™ of 51/100 and a GF Value™ of €1.55 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Editas Medicine's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.205. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.86 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-21), Editas Medicine's current stock price is €2.51. Editas Medicine's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1.86. Editas Medicine's Cyclically Adjusted Price-to-FCF of today is .


Editas Medicine  (STU:8EM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Editas Medicine Cyclically Adjusted FCF per Share Related Terms


Editas Medicine Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine Cyclically Adjusted FCF per Share Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.73 -1.80

Editas Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.81 -1.94 -1.80 -1.80 -1.86

STU:8EM vs SGMT, AUTL, FBRX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Editas Medicine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Cyclically Adjusted Price-to-FCF falls into.


STU:8EM
51GF Score
Editas Medicine Inc STU:8EM
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Editas Medicine's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.205/330.2130*330.2130
=-0.205

Current CPI (Mar. 2026) = 330.2130.

Editas Medicine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.279 241.018 -0.382
201609 -0.446 241.428 -0.610
201612 -0.381 241.432 -0.521
201703 1.772 243.801 2.400
201706 -0.578 244.955 -0.779
201709 -0.584 246.819 -0.781
201712 -0.503 246.524 -0.674
201803 -0.414 249.554 -0.548
201806 -0.330 251.989 -0.432
201809 -0.159 252.439 -0.208
201812 -0.002 251.233 -0.003
201903 -0.539 254.202 -0.700
201906 -0.493 256.143 -0.636
201909 -0.531 256.759 -0.683
201912 0.678 256.974 0.871
202003 -0.932 258.115 -1.192
202006 -0.525 257.797 -0.672
202009 -0.766 260.280 -0.972
202012 -0.547 260.474 -0.693
202103 -0.631 264.877 -0.787
202106 -0.509 271.696 -0.619
202109 -0.537 274.310 -0.646
202112 -0.485 278.802 -0.574
202203 -0.682 287.504 -0.783
202206 -0.530 296.311 -0.591
202209 -0.714 296.808 -0.794
202212 -0.589 296.797 -0.655
202303 -0.510 301.836 -0.558
202306 -0.518 305.109 -0.561
202309 -0.410 307.789 -0.440
202312 -0.264 306.746 -0.284
202403 -0.581 312.332 -0.614
202406 -0.683 314.175 -0.718
202409 -0.606 315.301 -0.635
202412 -0.593 315.605 -0.620
202503 -0.534 319.799 -0.551
202506 -0.516 322.561 -0.528
202509 -0.296 324.800 -0.301
202512 -0.320 324.054 -0.326
202603 -0.205 330.213 -0.205

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.86 mean?
Editas Medicine (STU:8EM) has a Cyclically Adjusted FCF per Share of €-1.86 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's Cyclically Adjusted FCF per Share too high?
Editas Medicine's current Cyclically Adjusted FCF per Share is €-1.86. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Cyclically Adjusted FCF per Share compare to SGMT and AUTL?
Editas Medicine's Cyclically Adjusted FCF per Share of €-1.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Editas Medicine and its competitors. Editas Medicine's current Cyclically Adjusted FCF per Share is €-1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (STU:8EM) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.55, compared to a current price of €2.51 — trading 61.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.86. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Editas Medicine (STU:8EM), the current Cyclically Adjusted FCF per Share is €-1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (STU:8EM) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of €2.51 is trading 61.9% above its estimated GF Value™ of €1.55. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for STU:8EM:

  • Cyclically Adjusted FCF per Share: €-1.86
  • GF Value™: €1.55 vs. price of €2.51 (61.9% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the STU:8EM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Editas Medicine Business Description

Other Exchanges EDIT:USA0IFK:UK
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for STU:8EM

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.51
Price
€1.55
GF Value